Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

LadRx Corporation

Company price
0.0003 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
10
Market Cap
0.74M
P/E
4.29

Momentum Score

…

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company's Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.11
High
52 Week Price Range
0.05
Low
10.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly listed on the OTCQB, LadRx Corporation has limited publicly available disclosures about its business operations and strategic plans. Because filings and communications are sparse, major long-term growth drivers are not clearly stated and appear dependent on future corporate developments; investors may find its early-stage, small-cap profile could support upside if management executes and provides more transparent information.
Primary risks include limited disclosure and transparency, low trading liquidity, likely need for external financing, and execution and regulatory uncertainties that could materially affect prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
0.10%
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
31.40%
Net Debt
-
ROCE
-7698.22%
Diluted EPS TTM
0.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -4.20M -13.18M -6.70M -7.52M -9.08M
Net income -4.20M -13.18M -6.70M -7.16M -12.71M
Selling general administrative 4.54M 5.97M 6.00M 7.44M 8.08M
Reconciled depreciation 0.02M 0.01M 0.23M 0.02M 0.03M
Ebit -4.56M -5.98M -6.83M -7.86M -8.25M
Ebitda -4.54M -5.97M -6.60M -7.50M -7.33M
Operating income -4.56M -5.98M -6.83M -7.86M -8.25M
Interest expense - - - 0.00M 1.72M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income 0.01M 0.02M 0.12M 0.35M 0.36M
Net interest income 0.01M 0.02M 0.12M 0.35M -1.36M
Income tax expense - - 0.00M 0.00M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.25M
Total operating expenses 4.56M 5.98M 6.83M 7.86M 8.50M
Total other income expense net 0.35M -7.21M 0.01M -0.01M 0.53M
Discontinued operations - - - 0.36M -3.63M
Net income from continuing ops -4.20M -13.18M -6.70M -7.52M -9.08M
Net income applicable to common shares -4.76M -13.35M -6.70M -7.16M -12.71M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 2.25M 8.73M 12.06M 17.26M 22.93M
Other current assets 0.63M 1.31M 1.09M 1.07M 0.08M
Total liab 2.22M 3.95M 3.19M 2.05M 2.56M
Total stockholder equity 0.03M 4.78M 8.87M 15.20M 20.36M
Other current liab 0.02M 0.01M 0.02M 0.00M 0.63M
Common stock 0.05M 0.04M 0.04M 0.03M 0.03M
Capital stock 1.39M 4.06M 0.04M 0.03M 0.03M
Retained earnings -488.84M -484.08M -470.73M -464.03M -456.86M
Good will - - - - 0.00M
Other assets 0.01M 0.02M 0.02M 0.01M 0.37M
Cash 1.37M 6.77M 10.00M 16.13M 21.37M
Total current liabilities 2.19M 3.73M 2.77M 2.05M 2.56M
Property plant equipment 0.24M 0.43M 0.62M 0.04M 0.04M
Total current assets 2.00M 8.28M 11.42M 17.20M 22.52M
Net tangible assets -1.32M 0.75M 8.87M 15.20M 20.36M
Net receivables 0.00M 0.20M 0.33M 0.01M 0.15M
Accounts payable 0.98M 1.47M 1.40M 0.89M 1.23M
Non currrent assets other 0.01M 0.02M 0.02M 0.01M 0.37M
Non current assets total 0.24M 0.45M 0.64M 0.05M 0.41M
Capital lease obligations 0.23M 0.42M 0.60M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.00M -0.01M -0.03M 0.48M -0.01M
Change to liabilities -0.49M 0.07M 0.19M -0.35M -2.83M
Total cashflows from investing activities -0.00M -0.01M -0.03M 0.48M -0.01M
Net borrowings - - - - -9.99M
Total cash from financing activities -0.56M 9.08M 0.04M 0.04M -5.25M
Change to operating activities -0.34M 0.60M -0.19M 0.32M -6.39M
Net income -4.20M -13.18M -6.70M -7.16M -12.71M
Change in cash -5.39M -3.23M -6.13M -5.24M -16.12M
Begin period cash flow 6.77M 10.00M 16.13M 21.37M 37.50M
End period cash flow 1.37M 6.77M 10.00M 16.13M 21.37M
Total cash from operating activities -4.83M -12.31M -6.14M -5.72M -10.87M
Issuance of capital stock 0.00M 9.18M - 0.00M 6.51M
Depreciation 0.20M 0.20M 0.23M 0.02M 0.03M
Other cashflows from investing activities - - - 0.50M 0.50M
Dividends paid 0.56M 0.17M 0.17M 0.17M 0.17M
Change to account receivables - - - 0.14M 7.36M
Other cashflows from financing activities - - - - -1.77M
Change to netincome 0.01M 0.01M 0.33M 1.31M 2.53M
Capital expenditures 0.00M 0.01M 0.03M 0.02M 0.01M
Change in working capital -0.66M 0.85M 0.00M 0.11M -1.87M
Stock based compensation 0.01M 0.00M 0.33M 2.01M -
Other non cash items - - - - 1.16M
Free cash flow -4.83M -12.32M -6.17M -5.74M -10.88M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
LADX
LadRx Corporation
-
-%
0.00 4.29 - 34.48 0.51 0.61
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

LadRx Corporation

LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company's Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

11726 San Vicente Boulevard, Los Angeles, CA, United States, 90049

310 826 5648

3

Name Title Year Born
Mr. John Y. Caloz CFO, Treasurer & Sr. VP 1952
Dr. Stephen Snowdy Ph.D. Chief Exec. Officer 1970
Molly Carey Poarch Global & U.S. Head of Corp. Communications NA
Ms. Molly Painter Pres of USA and Head of Launch & Commercial Operations 1976
Terri Stevens Chief Bus. Officer NA
Ms. Cristina Newman Corp. Sec. NA
Dr. Felix Kratz Ph.D. Sr. VP, Drug Devel. 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…